Biomea Fusion to Host Conference Call to Announce Topline Results From Phase II COVALENT-111 Study in Patients With Type 2 Diabetes (T2D)
Biomea Fusion to Host Conference Call to Announce Topline Results From Phase II COVALENT-111 Study in Patients With Type 2 Diabetes (T2D)
Tuesday, December 17, 2024 at 8:00 am EST
2024年12月17日,星期二,東部標準時間上午8:00
REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Tuesday, December 17, 2024 at 8:00 am EST to present topline results from COVALENT-111, the company's Phase II trial of icovamenib in patients with type 2 diabetes.
加利福尼亞州紅木城,2024年12月16日(全球新聞社)-- Biomea Fusion, Inc.("Biomea")(納斯達克:BMEA)是一家臨床階段的生物製藥公司,致力於發現和開發口服共價小分子藥物,以治療和改善糖尿病、肥胖症以及遺傳性癌症患者的生活。今天宣佈將於2024年12月17日星期二上午8:00東部標準時間召開電話會議和網絡廣播,以呈現COVALENt-111的初步結果,這是該公司在2型糖尿病患者中進行的icovamenib II期臨床試驗。
Conference Call and Webcast Details
Webcast of Biomea's investor update on Tuesday, December 17, 2024, at 8:00 am EST will be available to registered attendees under the Investors and Media section of the company's website at . A replay of the presentation will be archived on Biomea's site following the event.
電話會議和網絡直播細節
Biomea投資者更新的網絡廣播將於2024年12月17日(星期二)上午8:00(東部標準時間)在公司網站的投資者和媒體部分提供給註冊的與會者, 演示的重播將在活動後存檔在Biomea的網站上。
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
關於Biomea Fusion
Biomea Fusion是一家處於臨床階段的生物製藥公司,專注於發現和開發口服共價小分子,以改善糖尿病、肥胖症和遺傳性癌症患者的生活。共價小分子是一個合成化合物,能永久性地與其目標蛋白形成結合,並且相比於傳統的非共價藥物,提供了許多潛在的優勢,包括更高的靶向選擇性、更低的藥物暴露和能夠驅動更深、更持久的反應。
We are utilizing our proprietary FUSION System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
我們正在利用我們專有的FUSION系統來發現、設計和開發一系列下一代共價結合小分子藥物,旨在最大化患者的臨床獲益。我們希望對我們服務的患者的疾病治療產生重大影響。我們的目標是治癒。
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
請訪問我們的官方網站 biomeafusion.com,並關注我們 LinkedIn, X 和 臉書.
Contact:
Ramses Erdtmann
COO & President of Biomea Fusion
re@biomeafusion.com
聯繫:
拉美西斯·埃爾德特曼
Biomea Fusion 的首席運營官兼總裁
re@biomeafusion.com